Summit Therapeutics Inc. (NASDAQ: SMMT) will present data from its investigational bispecific antibody ivonescimab at the European Lung Cancer Congress in Copenhagen on March 27, 2026.

The company will display three posters featuring updated data from Phase III studies in advanced non-small cell lung cancer patients. The presentations will occur from 1:00 to 2:00 pm Central European Time.

One poster will present intracranial efficacy data from the global HARMONi study, showing ivonescimab plus chemotherapy improved intracranial progression-free survival compared to chemotherapy alone in patients with EGFR-mutated NSCLC previously treated with EGFR tyrosine kinase inhibitors. In patients with baseline brain metastases, the combination achieved 10.1 months versus 6.5 months for chemotherapy alone, with a hazard ratio of 0.53.

The second poster will examine health-related quality of life data from the same HARMONi trial population. The third poster will present quality of life data comparing ivonescimab monotherapy to pembrolizumab monotherapy from the HARMONi-2 study conducted in China by collaboration partner Akeso Inc. (HKEX: 9926.HK).

Ivonescimab is designed as a bispecific antibody that blocks both PD-1 and VEGF pathways. The drug received Fast Track designation from the FDA for the HARMONi clinical trial setting. Summit submitted a Biologics License Application to the FDA in January 2026, with a target review date of November 14, 2026.

The company is conducting multiple Phase III trials with ivonescimab across different cancer types, including ongoing studies in lung cancer and colorectal cancer. Akeso previously reported positive results from three Phase III trials conducted in China.